Helen Torley, who serves as President and CEO of Halozyme Therapeutics (NASDAQ: HALO), conducted a series of insider transactions on April 1 and April 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
Across multiple trades on those two days Torley sold a total of 39,000 shares of Halozyme common stock for roughly $2.59 million. The per-share sale prices recorded in the filing ranged from $64.063 to $65.714. At the time of reporting the stock is trading at $64.49, which implies a market capitalization of about $7.63 billion.
Concurrently, Torley exercised options to acquire 40,000 shares of Halozyme common stock at an exercise price of $12.07 per share, for a cash outlay of $482,800. The Form 4 discloses both the option exercises and the subsequent open-market sales.
Independent analysis cited in the filing notes that, despite the insider sale, InvestingPro's Fair Value calculation indicates the shares remain undervalued. The company is trading at a price-to-earnings ratio of 24.91 and is reported to have a return on equity of 154%.
Halozyme also released quarterly financial results showing a sizable increase in revenue for the fourth quarter. Revenue rose 52% year-over-year to $451.8 million, beating analyst estimates of $393.9 million. However, on a non-GAAP basis the company recorded a diluted loss per share of $0.24 for the period, a result that company filings attribute largely to acquisition-related write-offs. This contrasted with analyst expectations of a $1.90 profit per share.
Following the fiscal report, Benchmark raised its price target on Halozyme to $90 and maintained a Buy rating. TD Cowen likewise lifted its price target to $96, citing the company’s strong fiscal results and a newly disclosed mix of royalty revenue.
In corporate leadership news included with the filings, Halozyme announced the appointment of David Ramsay as Interim Chief Financial Officer. Ramsay previously served as Halozyme’s CFO from 2003 to 2009 and again from 2013 to 2015.
The company’s press materials also reference a regulatory milestone reported by a partner: the U.S. Food and Drug Administration approved Johnson & Johnson’s TECVAYLI, when used in combination with DARZALEX FASPRO, for the treatment of relapsed or refractory multiple myeloma. That approval was based on data from the Phase 3 MajesTEC-3 study, according to the Halozyme press release.
All of the insider activity and option exercises are documented in the Form 4 filing submitted to the SEC. The filing lists the specific trade dates, share counts, exercise price and sale price ranges that are summarized above.